Articles Tagged With:
-
Infant Botulism
As of early December 2025, a commercially prepared infant formula distributed throughout the United States was linked to 39 cases of life-threatening infant botulism in 18 states.
-
Spirituality: The Missing Pillar of Whole-Person Care
Spirituality is a critical yet often overlooked component of whole-person care. Evidence shows that attending to patients’ spiritual needs can improve coping, reduce anxiety and depression, and enhance satisfaction with care, while also strengthening the therapeutic relationship. Importantly, integrating spiritual care also supports clinician well-being by reconnecting providers with purpose and mitigating burnout, making it beneficial for both patients and practitioners.
-
Pediatric Facial Trauma
Pediatric facial trauma is common, and clinicians require an understanding not only of common injury patterns, but also of recommended diagnostic strategies and evidence-based management approaches.
-
Can You Be Certain?
You are asked for your opinion on this electrocardiogram (ECG). No history is available. Can you be certain of your diagnosis?
-
Remibrutinib Tablets (Rhapsido)
The U.S. Food and Drug Administration has approved a second Bruton’s tyrosine kinase inhibitor (BTKi), remibrutinib, for the treatment of chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite antihistamine treatment. The first BTKi, rilzabrutinib (Wayrilz), was approved for chronic immune thrombocytopenia. Remibrutinib is distributed by Novartis Pharmaceuticals Corporation as Rhapsido.
-
Spironolactone for the Treatment of Acne Vulgaris
In this meta-analysis of 563 patients from five randomized controlled trials, objective assessment of acne improvement was higher in the spironolactone group compared to the placebo group (odds ratio, 6.59; 95% confidence interval, 3.50-12.43).
-
Cephalexin Beat Cefdinir for Treating Uncomplicated UTI in Women
Cefdinir was inferior to cephalexin in the treatment of uncomplicated urinary tract infections in women due to a high rate of early recurrence.
-
Defining Normal Ascending Aorta Size by Imaging
Two large biobank studies of the relationship between various imaging measurements of ascending aorta size normalized to several body size metrics have shown that ascending aorta area/height performs best for predicting adverse aortic events.
-
Total Steps vs. How You Get Them and the Risk of Cardiovascular Events
In a large U.K. Biobank study of subjects who performed a one-week determination of steps/day, those who achieved < 8,000 steps/day were categorized by the duration of their step acquisition periods and were followed for a mean of eight years. All-cause mortality and the development of cardiovascular disease (CVD) were greater in those with short step acquisition periods (< 5 minutes) as compared to those with longer periods (> 15 minutes). Thus, longer step acquisition bouts are more effective in reducing mortality and CVD in those with less-than-ideal total daily step counts.
-
Value of Natriuretic Peptide Measurements in HFpEF
A pooled analysis of four trials of drug therapy for heart failure with preserved ejection fraction (HFpEF) patients has shown that, although the risk of adverse outcomes is higher with increasing baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, the effect is attenuated at higher body mass index levels, such that lower NT-proBNP cutoffs for risk-stratifying obese patients need to be developed.